Current share price for ZLD : $0.480 0.01 (2.04%)
Zelira Therapeutics Limited (ZLD), an ASX-listed company, is a global biopharmaceutical company in the research, development and commercialisation of clinically validated cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development positioned to enter global markets.
ASX Code | ZLD |
Website | http://www.zeliratx.com |
Industry/Sector | Pharmaceuticals |
Market Cap ($M) | 5 |
ZLD Share Price | $0.480 |
Day High | $0.490 |
Day Low | $0.480 |
Last Close | $0.490 |
ZLD Share Price Movement | $0.01 ( 2.04% ) |
There are no dividends for Zelira Therapeutics Limited (ZLD). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Headline | Annoucement date/time+ | Price at announcement+ | Current price+ | Price 7D Avg | Gain/Loss |
---|---|---|---|---|---|
Appendix 4C Cash Flow Report | 29 Apr 2024 5:10PM | $0.715 | $0.480 | $0.520 | fallen by 32.87% |
March 2024 Quarterly Activities Report | 29 Apr 2024 5:09PM | $0.715 | $0.480 | $0.520 | fallen by 32.87% |
Zelira receives $919,000 R&D Tax Incentive Scheme Refund | 15 Apr 2024 11:16AM | $0.690 | $0.480 | $0.520 | fallen by 30.43% |
See all ASX announcements from Zelira Therapeutics Limited (ZLD) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
---|---|---|---|---|---|---|---|
2023A | -$6.52 | -$57.80 | -61.10% | 0.00 | 0.00 | 0.00% | 0.0% |
2022A | -$12.41 | -$148.50 | 15.20% | 0.00 | 0.00 | 0.00% | 0.0% |
2021A | -$8.55 | -$128.90 | -10.90% | 0.00 | 0.00 | 0.00% | 0.0% |
Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
---|---|---|---|---|---|---|---|---|---|---|
2021 A | 2022 A | 2023 A | 2021 A | 2022 A | 2023 A | 2021 A | 2022 A | 2023 A | ||
Mayne Pharma Group (MYX) | $488M | 0.9287 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
Neuren Pharmaceuticals (NEU) | $2,683M | 799.6667 | -0.5504 | 0.6667 | 17.4938 | 38.9074 | 23.3444 | 0.00% | 0.00% | 0.00% |
Zelira Therapeutics (ZLD) | $6M | -0.6106 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
---|---|---|---|---|
Company | 0.00 | 0.00 | 0.17 | 0.00 |
Market | 0.45 | 14.50 | 1.11 | 1.12 |
Sector | 1.32 | 21.80 | 1.90 | 0.96 |
Name | Position | Start Date |
---|---|---|
Mr Timothy (Tim) Ryan Slate | Company Secretary, Non-Executive Director | 31 Jan 2022 |
Mr Greg Blake | Executive Director | 20 Feb 2023 |
Dr Oludare Odumosu | Managing Director | 4 Dec 2019 |
Mr Osagie Imasogie | Non-Executive Chairman, Non-Executive Director | 4 Dec 2019 |
Dr Donna Gentile O'Donnell | Non-Executive Director | 1 Jun 2023 |
Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
---|---|---|---|---|---|---|
24 Nov 2023 | SLATE, Timothy (Tim) | Issued | Options | 100,000 | $0.473 | $47,335.000 |
24 Nov 2023 | IMASOGIE, Osagie | Issued | Options | 150,000 | $0.473 | $71,002.000 |
24 Nov 2023 | BLAKE, Greg | Issued | Options | 175,000 | $0.473 | $82,836.000 |
See all changes in directors' interest & trades for Zelira Therapeutics Limited (ZLD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Zelira Therapeutics Limited (ZLD). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
Holding | Name |
---|---|
1,134,644 (10%) | Malik Majeed |
Date | Event |
---|---|
20 February 2025 | Report (Interim) |
29 October 2024 | Report (Quarterly) |
27 September 2024 | Report (Annual) |
29 August 2024 | Report (Prelim) |
Zelira Therapeutics Limited's (ZLD) current share price is $0.48. This constitutes a price movement of 7.69% when compared to the share price 7 days ago and is -84.26% below ZLD's 12-month high of $3.05 per share. Prices are delayed by at least 20 minutes.
Relative to the previous close share price of $0.49, Zelira Therapeutics Limited's (ZLD) current share price of $0.48 constitutes a movement of -$0.01 or -2.04%. Zelira Therapeutics Limited's (ZLD) share price movement is -7.69% when compared to 7 days ago and is -84.26% below ZLD's 52-week high of $3.05.
Zelira Therapeutics Limited's (ZLD) 52-week high is $3.05 which was reached on 31 May 2023. Relative to this, ZLD's current share price of $0.48 constitutes a -$2.57 or -84.26% drop since that high of $3.05 per ZLD share.
Zelira Therapeutics Limited's (ZLD) 52-week low is $0.48 which was reached on 21 May 2024. Relative to this, ZLD's current share price of $0.48 constitutes a or 0% drop since that low of $0.48 per ZLD share.
Over the last 12 months, Zelira Therapeutics Limited (ZLD) has a daily average trading volume of 15,754 ZLD shares per day.
Zelira Therapeutics Limited (ZLD) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for ZLD is a ratio that tells you the percentage of Zelira Therapeutics Limited's (ZLD) share price that it pays out in dividends each year.
Zelira Therapeutics Limited (ZLD) will release its next Annual Report on 27 September 2024. Zelira Therapeutics Limited's (ZLD) last annual report was released on 29 Sep 2023. Click here to view Zelira Therapeutics Limited's (ZLD) last annual report.
Zelira Therapeutics Limited (ZLD) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), ResMed Inc. (RMD), Cochlear Limited (COH), and Fisher & Paykel Healthcare Corporation Limited (FPH).
The price-to-earnings (P/E) ratio for Zelira Therapeutics Limited (ZLD) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Zelira Therapeutics Limited's (ZLD) share price to its earnings per ZLD share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.